Of 62 patients with INI1/SMARCB1 deleted/mutated epithelioid cancers, the ORR was 15% at data cut‐off, and an additional 26% exhibited disease control at 32 weeks of treatment. This evidence concerns the gene SMARCB1 and cancer.